Nephrol Dial Transplant. 2011 Jan;26(1):28-35. doi: 10.1093/ndt/gfq576. Epub 2010 Nov 2.
'Diabesity' is the term for diabetes occurring in the context of obesity. In this review, we will overview the latest epidemiological data available describing the rising prevalence, health impact and economic impact of diabesity. We will also outline the measures required to slowdown this newly evolving epidemic. The global prevalence of diabetes in 2010 was 284 million people worldwide constituting around 6.4% of the world population, which is higher than was projected in earlier studies. Furthermore, the projections for 2030 show the prevalence to reach 439 million individuals comprising ~7.7% of the world population. The burden of diabetes on the world economy has been rising steadily in the last decade to reach $376 billion in 2010 and is expected to reach $490 billion in 2030. Diabesity represents a substantial economic burden as reflected by diabetes and obesity consuming 14 and 5.7% of the USA's total health expenditure, respectively, representing the highest known expenditure on diabesity worldwide. When costs associated with being overweight were also included, the upper limit of obesity expenditure rises to 9.1% of the USA's total healthcare expenditure. The highest recorded expenditure on diabetes alone was in Saudi Arabia consuming 21% of the country's total health expenditure, with no data available about the health expenditure on obesity. The health impact of diabesity is substantial to include long-term diabetic complications, reduction in health-related functioning, reduction of quality of life and reduced overall life expectancy. Long-term complications include myocardial infarction, cerebrovascular stroke and end-stage renal disease. Also recent advances have found that there is an association between chronic stress, depression and sleeping troubles to both diabetes and obesity. This century is the unprecedented diabetogenic era in human history. It is thus urgent to take steps including screening, prevention and early management in an attempt to control this evolving epidemic of diabesity.
“糖胖病”是指肥胖人群中出现的糖尿病。在这篇综述中，我们将概述最新的流行病学数据，描述糖胖病发病率的上升、对健康的影响和对经济的影响。我们还将概述减缓这一新兴流行病的措施。2010 年，全球糖尿病患病率为 2.84 亿人，占世界人口的 6.4%，高于早期研究的预测。此外，2030 年的预测显示，患病率将达到 4.39 亿人，占世界人口的 7.7%。在过去十年中，糖尿病对世界经济的负担一直在稳步上升，2010 年达到 3760 亿美元，预计到 2030 年将达到 4900 亿美元。糖胖病的经济负担很大，因为糖尿病和肥胖症分别占美国总卫生支出的 14%和 5.7%，这是全球已知的糖胖病最高支出。当包括超重相关成本时，肥胖症支出上限上升至美国总医疗保健支出的 9.1%。记录的糖尿病支出最高的是沙特阿拉伯，占该国总卫生支出的 21%，而关于肥胖症的卫生支出则没有数据。糖胖病对健康的影响是巨大的，包括长期的糖尿病并发症、健康相关功能下降、生活质量下降和总体预期寿命缩短。长期并发症包括心肌梗死、脑血管意外和终末期肾病。最近的研究进展还发现，慢性压力、抑郁和睡眠问题与糖尿病和肥胖症都有关联。本世纪是人类历史上前所未有的糖尿病致病时代。因此，迫切需要采取包括筛查、预防和早期管理在内的措施，试图控制这一不断演变的糖胖病流行。
